We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CGNSF market cap is 1.16M. The company's latest EPS is CAD -0.0830 and P/E is -0.12.
| Year End 31 January 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 45k |
| Operating Income | -3.23M | -1.62M | -1.79M | -9.44M | -5.07M |
| Net Income | -4.19M | -2.65M | -1.93M | -13.13M | -7.43M |
| Year End 31 January 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 716k | 748k | 1.83M | 2.01M | 2.83M |
| Total Liabilities | 237k | 1.01M | 965k | 7.68M | 12.72M |
| Total Equity | 479k | -263k | 863k | -5.68M | -9.89M |
| Year End 31 January 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -3.49M | -1.86M | -1.96M | -3.21M | -5.94M |
| Investing | 3.32M | 107k | -49k | -100k | -70k |
| Financing | 298k | 2.08M | 2.79M | 3.33M | 6.88M |
| Market Cap | 1.16M |
| Price to Earnings Ratio | -0.12 |
| Price to Sales Ratio | 20 |
| Price to Cash Ratio | 0.4 |
| Price to Book Ratio | -0.09 |
| Dividend Yield | - |
| Shares Outstanding | 89.59M |
| Average Volume (1 week) | 1.07k |
| Average Volume (1 Month) | 16.9k |
| 52 Week Change | -93.55% |
| 52 Week High | 0.2452 |
| 52 Week Low | 0.01 |
| Spread (Intraday) | 0.01 (41.71%) |
| Company Name | Cognetivity Neurosciences Ltd (PK) |
| Address |
suite 1500, 1055 w. georgia st vancouver, british columbia V6E 4N7 |
| Website | https://www.cognetivity.com |
| Industry | medical laboratories (8071) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
